Blog

Archive for the ‘bioengineering’ category: Page 138

May 8, 2019

Anti-Aging Gene Therapy for Dogs Coming This Fall

Posted by in categories: bioengineering, biotech/medical, life extension

In an article last May, we covered how Rejuvenate Bio, a startup biotech company led by Professor George Church, was planning to reverse aging in dogs as a step towards bringing these therapies to us. Those plans are now starting to move forward with news of a trial launch in the fall later this year.

Developing anti-aging therapies in dogs is the first step

Back in 2015, the Church lab at Harvard began testing a variety of therapies focused on age reversal using CRISPR, a gene editing system that was much easier and faster to use than older techniques. Since then, Professor Church and his lab have conducted a myriad of experiments and gathered lots of data with which to plan future strategies for tackling aging.

Continue reading “Anti-Aging Gene Therapy for Dogs Coming This Fall” »

May 7, 2019

CRISPR Used in Human Trials for the First Time in the US

Posted by in categories: bioengineering, biotech/medical

Here, doctors extract a patient’s own T cells, a type of white blood cell that normally acts as the body’s watcher against cancer and infection. Cancer cells eventually learn to evade T cells or disarm the troops—while turning their own surrounding normal cells into cancerous ones, thus expanding their tumor legion.

CAR-T uses gene therapy to recharge those beaten-down T cells. The UPenn study, for example, relies on a neutered HIV-like virus to deliver an artificial “tracker” protein into those cells. These designer trackers expertly hunt down a protein dubbed NY-ESO-1, which dot certain cancer cells’ surface like a homing beacon.

CRISPR amplifies the CAR-T effect: the team is using the gene editing tool to erase three different “brakes” in T cells. Killing off the first two, TCR α and TCR β, keeps the edited cells in check to prevent friendly autoimmune fire, and allows the added “tracker proteins” to thrive in large numbers. Wiping out the third, PD-1, prevents a phenomenon called T cell exhaustion. It’s aptly named: here, tumor cells secrete molecules that literally shut down T cell activity, zapping away their killing power.

Continue reading “CRISPR Used in Human Trials for the First Time in the US” »

May 7, 2019

Nanoblades Are Another Delivery Option for Gene Editing into Live Organisms

Posted by in categories: bioengineering, biotech/medical, genetics

Targeted genome editing tools, such as meganucleases (MGN), zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALENs) and more recently the clustered regularly interspaced short palindromic repeats (CRISPR) have revolutionized most biomedical research fields. Such tools allow to precisely edit the genome of eukaryotic cells by inducing double-stranded DNA (dsDNA) breaks at specific loci. Relying on the cell endogenous repair pathways, dsDNA breaks can then be repaired by non-homologous end-joining (NHEJ) or homology-directed repair (HDR) allowing the removal or insertion of new genetic information at a desired locus.

Among the above-mentioned tools, CRISPR-Cas9 is currently the most simple and versatile method for genome engineering. Indeed, in the two-component system, the bacterial-derived nuclease Cas9 (for CRISPR-associated protein 9) associates with a single-guide RNA (sgRNA) to target a complementary DNA sequence and induce a dsDNA break. Therefore, by the simple modification of the sgRNA sequence, users can specify the genomic locus to be targeted. Consistent with the great promises of CRISPR-Cas9 for genome engineering and gene therapy, considerable efforts have been made in developing efficient tools to deliver the Cas9 and the sgRNA into target cells ex vivo either by transfection of plasmids coding for the nucleases, transduction with viral-derived vectors coding for the nucleases or by direct injection or electroporation of Cas9-sgRNA complexes into cells.

Researchers have designed Nanoblades, a protein-delivery vector based on friend murine leukemia virus (MLV) that allows the transfer of Cas9-sgRNA ribonucleoproteins (RNPs) to cell lines and primary cells in vitro and in vivo. Nanoblades deliver the ribonucleoprotein cargo in a transient and rapid manner without delivering a transgene and can mediate knock-in in cell lines when complexed with a repair template. Nanoblades can also be programmed with modified Cas9 proteins to mediate transient transcriptional activation of targeted genes.

Continue reading “Nanoblades Are Another Delivery Option for Gene Editing into Live Organisms” »

May 7, 2019

Cryptic mutation is cautionary tale for crop gene editing

Posted by in categories: bioengineering, biotech/medical, food, genetics

Even in this “age of the genome,” much about genes remains shrouded in mystery. This is especially true for “cryptic mutations”—mutated genes that are hidden, and have unexpected effects on traits that are only revealed when combined with other mutations. Learning from one infamous cryptic mutation in particular, researchers from CSHL share important lessons for breeding or gene editing in crops.

This story starts with the Campbell Soup Company and a field of tomatoes in the mid 20th century. One particular tomato plant had an unexpected beneficial trait: the fruits separated from the vine right where the green cap and stem touch the rest of the fruit. It turned out that this spontaneous natural mutant was ideal for large-scale production.

Continue reading “Cryptic mutation is cautionary tale for crop gene editing” »

May 7, 2019

Ekaterina Bereziy, CEO of ExoAtlet, a Russian company developing medical exoskeletons to enable people walk again — IdeaXme — Ira Pastor

Posted by in categories: aging, automation, bioengineering, bionic, biotech/medical, business, cyborgs, disruptive technology, robotics/AI, science

May 4, 2019

Anti-CRISPR molecules discovered that can block the gene editing technology

Posted by in categories: bioengineering, biotech/medical, habitats

As we dive into the brave new world of gene editing, CRISPR technologies are undoubtedly becoming increasingly precise, but alongside enhanced precision is also the necessity for developing ways to inhibit or block the process – an anti-CRISPR molecule, if you will. New work from the Broad Institute and Brigham and Women’s Hospital has presented a study that homes in on small molecules that may have the ability to safely block the CRISPR gene editing process.

Read more

May 2, 2019

Ira S. Pastor — CEO, Bioquark Inc. — Midnight In The Desert Show — Dave Schrader

Posted by in categories: aging, bioengineering, biotech/medical, business, cryonics, DNA, genetics, health, life extension, singularity

https://www.youtube.com/watch?v=-KvghKch12o&t=1s

Apr 29, 2019

An Interview with Jose Cordeiro

Posted by in categories: bioengineering, biotech/medical, economics, finance, life extension, lifeboat, space

Jose Cordeiro is promoting the development of rejuvenation biotechnologies in Spain and the integration of Latin American immigrants into Spain’s aging society to maintain the country’s productivity. He was at the recent Undoing aging conference in Berlin and gave us an interview about his political goals.


At Undoing Aging 2019, jointly organized by SENS Research Foundation and Forever Healthy Foundation, there was a session focused on the ways to make healthy life extension and medical progress a greater part of the global agenda. Among the speakers there was Jose Cordeiro, the vice chair of Humanity Plus, director of The Millennium Project, fellow of the World Academy of Art and Science, and board member of the Lifeboat Foundation.

Continue reading “An Interview with Jose Cordeiro” »

Apr 28, 2019

The promise and perils of synthetic biology

Posted by in categories: bioengineering, biological

To understand them well, look to the past.

Read more

Apr 24, 2019

Genetically modified virus may shrink incurable brain cancers

Posted by in categories: bioengineering, biotech/medical, genetics, neuroscience

By Michael Le Page

People with incurable melanomas and brain or breast cancers are to get injections of tumour-fighting viruses.

The trial will test the safety of a virus that has been engineered to shrink tumours – an approach that holds promise for a range of cancers, including deadly brain tumours.

Continue reading “Genetically modified virus may shrink incurable brain cancers” »